Luye Pharma's Rykindo (risperidone) Receives the US FDA’s Approval for the Treatment of Schizophrenia and Bipolar 1 Disorder
Shots:
- Rykindo has received approval from the US FDA for extended-release injectable suspension for the treatment of schizophrenia & as monotx. or as adjunctive therapy to lithium or valproate for bipolar I disorder in adults
- Rykindo is a long-acting risperidone inj. & marks the first innovative therapy to be marketed in the US. The therapy was administered via IV, q2w uses long-acting, extended-release microsphere technology to deliver the active component, risperidone which was approved for marketing in China for schizophrenia
- Rykindo’s development is moving forward in the EU & the company is planning to launch the therapy in more countries and regions globally
Ref: Luye | Image: Luye Pharma
Related News:- Luye Pharma Receives NMPA’s Approval of World First Boyoubei (biosimilar, denosumab) to Treat Postmenopausal Women with Osteoporosis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
